FibroGen (NASDAQ:FGEN) posted its earnings results on Monday. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.02, Briefing.com reports. FibroGen had a return on equity of 9.01% and a net margin of 13.90%. The business had revenue of $33.17 million during the quarter, compared to analyst estimates of $31.61 million. During the same quarter last year, the firm earned ($0.50) earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.
Shares of FGEN traded down $0.76 on Tuesday, hitting $34.64. The company’s stock had a trading volume of 26,941 shares, compared to its average volume of 810,108. The company has a market capitalization of $3.62 billion, a PE ratio of -33.86 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.73 and a quick ratio of 9.71. FibroGen has a fifty-two week low of $33.51 and a fifty-two week high of $61.23. The company has a 50 day moving average price of $38.61 and a 200 day moving average price of $41.88.
In related news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total value of $1,757,063.88. Following the completion of the transaction, the chief executive officer now owns 2,356,578 shares in the company, valued at approximately $104,467,102.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $36.58, for a total transaction of $205,762.50. Following the completion of the transaction, the senior vice president now owns 145,253 shares of the company’s stock, valued at approximately $5,313,354.74. The disclosure for this sale can be found here. Insiders sold a total of 86,756 shares of company stock worth $3,644,083 over the last three months. 7.83% of the stock is owned by company insiders.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: Cash Asset Ratio
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.